Daratumumab;Daratumumab - 20mg/ml in water;Daratumumab 21.7mg/ml;Daratumumab USP/EP/BP;Research Grade Daratumumab(DHD80801);Anti-Human CD38, Human Antibody,myeloma,inhibit,tumor,antibody,cell,adhesion,cytotoxicity,Inhibitor,Daratumumab;Research Grade Daratumumab;Daratumumab - 20mg/ml in buffer
用途
Treatment of relapsed multiple myeloma in patients who have received prior therapy with a proteasome inhibitor and an immunomodulatory agent; induction of tumor cell death through multiple mechanisms by targeting CD38, a transmembrane ectoenzyme highly expressed on the surface of multiple myeloma cells.